3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Stomach Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Vomiting
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Nodule
1
Thyroid Neoplasms
1
Thromboembolism
1
Thrombocytopenia
1
Stomatitis
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Scleroderma, Localized
1
Psoriasis
1
Postoperative Hemorrhage
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Cyst
1
Pain, Postoperative
1
Pain
1
Interventions
Carboplatin
42
Etoposide
37
Cisplatin
23
Topotecan
22
Nivolumab
17
pembrolizumab
12
atezolizumab
12
Ipilimumab
10
Paclitaxel
9
durvalumab
8
Irinotecan
8
Radiosurgery
6
Pemetrexed
6
rovalpituzumab tesirine
5
Magnetic Resonance Spectroscopy
5
trioctyl phosphine oxide
4
trilaciclib
4
etoposide phosphate
4
berzosertib
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Dexamethasone
4
veliparib
3
tremelimumab
3
olaparib
3
carfilzomib
3
cabozantinib
3
Temozolomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Small Cell Lung Carcinoma
×
Saline Solution
×
Clear all
NCT03066778
2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3
Completed
453 enrolled
23 charts